PTCT:NASDAQ
PTC Therapeutics, Inc.
$62.56
arrow_downward
-1.06%(-0.67) 1D
$62.56
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 8, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PTCT...
Open
$62.66
High
$62.86
Low
$61.65
Mkt. cap
5.22B
Avg. vol.
1.13M
Volume
826.57K
52-wk high
$90.87
52-wk low
$61.23
EPS
-$0.56
Beta
0.49
Shares outstanding
83.46M
No. of employees
991
Open
$62.66
High
$62.86
Low
$61.65
Mkt. cap
5.22B
Avg. vol.
1.13M
Volume
826.57K
52-wk high
$90.87
52-wk low
$61.23
EPS
-$0.56
Beta
0.49
Shares outstanding
83.46M
No. of employees
991
News stories
From web sources and news partners
GuruFocus
·
5 hours ago
PTCT Maintained by RBC Capital -- Price Target Lowered to $75
Yahoo Finance
·
16 hours ago
PTC Therapeutics, Inc. (PTCT) Stock Forecasts
MarketBeat
·
20 hours ago
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells $27,909.60 in Stock
Investing.com Canada
·
20 hours ago
Form 4 PTC Therapeutics Inc For: 7 October By Investing.com
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorBiotechnology
Websiteptcbio.com